Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Biomarker testing is essential to identify subgroups of NSCLC with oncogenic drivers that can be therapeutically targeted. These drivers are mainly found in lung adenocarcinomas (LUADs)
